Last reviewed · How we verify
Locapred@
Locapred is a topical corticosteroid that reduces inflammation and immune response in localized skin conditions.
Locapred is a topical corticosteroid that reduces inflammation and immune response in localized skin conditions. Used for Inflammatory skin conditions (specific indication in Phase 3 development unclear from available data).
At a glance
| Generic name | Locapred@ |
|---|---|
| Sponsor | Pierre Fabre Medicament |
| Drug class | Topical corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
As a corticosteroid, Locapred works by binding to glucocorticoid receptors in skin cells, suppressing inflammatory cytokine production and reducing immune cell infiltration. This leads to decreased erythema, pruritus, and other inflammatory manifestations in dermatological conditions. The topical formulation allows localized delivery while minimizing systemic exposure.
Approved indications
- Inflammatory skin conditions (specific indication in Phase 3 development unclear from available data)
Common side effects
- Skin atrophy
- Telangiectasia
- Striae
- Local irritation
Key clinical trials
- Alternation in the Human Microbiome With Commonly Used Topical Medications (PHASE1)
- URGO FilmoCream Eczema + Dermocorticoids in Atopic Dermatitis (NA)
- Proton Pump Inhibitors Use in Patients With Psoriasis (PHASE4)
- 8-Week Atopic Dermatitis (AD) Treatment Study (PHASE3)
- Evaluation of the Vasoconstriction Properties of MC2-01 Cream (PHASE1)
- Efficacy of Desonide (Desonatetm) Gel 0.05% in Younger and Older Subjects With Atopic Dermatitis (PHASE4)
- Comparison of the Efficacy and Safety of Two Topical Creams for Pediatric Atopic Dermatitis (PHASE4)
- Efficacy and Tolerability of New Topical Formulations in Subjects With Atopic Dermatitis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Locapred@ CI brief — competitive landscape report
- Locapred@ updates RSS · CI watch RSS
- Pierre Fabre Medicament portfolio CI